Skip to main content

Table 2 Characteristics of patients, tumour and treatment modalities by gendera

From: Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China

Variable All patient (N = 144)
n (%)
Females (N = 109)
n (%)
Males (N = 35)
n (%)
Part 1 Demographics
 Age (Median, IQR) 52.0 (46.0–61.8) 51.0 (45.5–58.0) 60.0 (51.0–72.0)
 Age (Range) 17–86 27–84 17–86
 Marital status
 Married 136 (94.4%) 104 (95.4%) 32 (91.4%)
 Single 2 (1.4%) 1 (0.9%) 1 (2.9%)
 Divorced 4 (2.8%) 3 (2.8%) 1 (2.9%)
 Widowed 1 (0.7%) 0 (0%) 1 (2.9%)
 Unknown 1 (0.7%) 1 (0.9%) 0 (0%)
Part 2 History of other diseases and symptoms
 History of smoking
  Yes 17 (11.8%) 3 (2.8%) 14 (40.0%)
  No 113 (78.5%) 96 (88.1%) 17 (48.6%)
  Unknown 14 (9.7%) 10 (9.2%) 4 (11.4%)
 History of cervical cancer
  Yes 2 (1.8%)
  No 89 (81.7%)
  Unknown 18 (16.5%)
 History of vulvar cancer
  Yes 2 (1.8%)
  No 89 (81.7%)
  Unknown 18 (16.5%)
 History of receptive anal intercourse or homosexual behavior
  Yes 0 (0%) 0 (0%) 0 (0%)
  No 113 (78.5%) 88 (80.7%) 25 (71.4%)
  Unknown 31 (21.5%) 21 (19.3%) 10 (28.6%)
 HIV status
  Positive 1 (0.7%) 0 (0%) 1 (2.9%)
  Negative 120 (83.3%) 91 (83.5%) 29 (82.9%)
  Unknown 23 (16.0%) 18 (16.5%) 5 (14.3%)
 Altered bowel habit
  Yes 32 (22.2%) 24 (22.0%) 8 (22.9%)
  No 112 (77.8%) 85 (78.0%) 27 (77.1%)
 Bleeding
  Yes 93 (64.6%) 75 (68.8%) 18 (51.4%)
  No 51 (35.4%) 34 (31.2%) 17 (48.6%)
 Pain
  Yes 47 (32.6%) 32 (29.4%) 15 (42.9%)
  No 97 (67.4%) 77 (70.6%) 20 (57.1%)
 Noticing a lump
  Yes 49 (34.0%) 35 (32.1%) 14 (40.0%)
  No 95 (66.0%) 74 (67.9%) 21 (60.0%)
 Perianal itch
  Yes 22 (15.3%) 17 (15.6%) 5 (14.3%)
  No 122 (84.7%) 92 (84.4%) 30 (85.7%)
 Tenesmus
  Yes 20 (13.9%) 14 (12.8%) 6 (17.1%)
  No 124 (86.1%) 95 (87.2%) 29 (82.9%)
Part 3 Characteristics of tumour
 Tumor site
  Anal margin 14 (9.7%) 8 (7.3%) 6 (17.1%)
  Anal canal 119 (82.6%) 95 (87.2%) 24 (68.6%)
  Both 5 (3.5%) 3 (2.8%) 2 (5.7%)
  Unknown 6 (4.2%) 3 (2.8%) 3 (8.6%)
 Tumor size
   ≤ 20 mm 35 (24.3%) 30 (27.5%) 5 (14.3%)
   > 20 mm 72 (50.0%) 55 (50.5%) 17 (48.6%)
  Unknown 37 (25.7%) 24 (22.0%) 13 (37.1%)
 T stage
  T1 13 (9.0%) 12 (11.0%) 1 (2.9%)
  T2 40 (27.8%) 29 (26.6%) 11 (31.4%)
  T3 28 (19.4%) 24 (22.0%) 4 (11.4%)
  T4 36 (25.0%) 27 (24.8%) 9 (25.7%)
  Unknown 27 (18.8%) 17 (15.6%) 10 (28.6%)
 N stage
  N0 52 (36.1%) 42 (38.5%) 10 (28.6%)
  N1 33 (22.9%) 25 (22.9%) 8 (22.9%)
  N2 22 (15.3%) 16 (14.7%) 6 (17.1%)
  N3 8 (5.6%) 7 (6.4%) 1 (2.9%)
  Unknown 29 (20.1%) 19 (17.4%) 10 (28.6%)
 M stage
  M0 110 (76.4%) 87 (79.8%) 23 (65.7%)
  M1 7 (4.9) 5 (4.6%) 2 (5.7%)
  Unknown 27 (18.8) 17 (15.6%) 10 (28.6%)
 AJCC stage
  I 10 (6.9%) 9 (8.3%) 1 (2.9%)
  II 22 (15.3%) 17 (15.6%) 5 (14.3%)
  III 61 (42.4%) 48 (44.0%) 13 (37.1%)
  IV 8 (5.6%) 6 (5.5%) 2 (5.7%)
  Unknown 43 (29.9%) 29 (26.6%) 14 (40.0%)
Part 4 SCC treatment
 Chemotherapy
  Yes 107 (74.3%) 82 (75.2%) 25 (71.4%)
  No 30 (20.8%) 21 (19.3%) 9 (25.7%)
  Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
 Radiotherapy
  Yes 101 (70.1%) 78 (71.6%) 23 (65.7%)
  No 36 (25.0%) 25 (22.9%) 11 (31.4%)
  Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
 Chemoradiotherapy
  Yes 97 (67.4%) 76 (69.7%) 21 (60.0%)
  No 40 (27.8%) 27 (24.8%) 13 (37.1%)
  Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
 Surgical operationb
 Yes 57 (39.6%) 44 (40.4%) 13 (37.1%)
 No 80 (55.6%) 59 (54.1%) 21 (60.0%)
 Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
  1. a: IQR interquartile range; AJCC American Joint Committee on Cancer; SCC squamous cell carcinomas; CRT Chemoradiotherapy
  2. b: Surgical operation did not include surgical biopsy for diagnosis